Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 5/2012

01-03-2012 | Review Article

Medical Therapy of Endometrial Cancer

Current Status and Promising Novel Treatments

Authors: Emily K. Hill, Dr Don S. Dizon, MD

Published in: Drugs | Issue 5/2012

Login to get access

Abstract

While early-stage endometrial cancer is often successfully treated with surgical intervention, treatment of advanced endometrial carcinoma can be difficult and prognosis poor, particularly in the context of metastatic or recurrent disease. Standard chemotherapy agents for both adjuvant first-line treatment (for selected patients deemed at high risk of relapse) and recurrent endometrial cancer include doxorubicin, platinum agents and paclitaxel. Investigational options currently being studied in phase II trials include both combined regimens of standard chemotherapeutic agents versus radiation as well as targeted treatments such as epothilones, mammalian target of rapamycin (mTOR) inhibitors and anti-angiogenic agents. Recent interest in the molecular pathways of carcinogenesis have lead to increased investigation of these novel agents and the hope that they will impact positively on the overall survival of women with endometrial cancer.
Literature
1.
2.
Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007; 335(7630): 1134PubMedCentralPubMedCrossRef
3.
Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569–78PubMedCrossRef
4.
Schmandt RE, Iglesias DA, Co NN, et al. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol 2011 Dec; 205(6): 518–25PubMedCrossRef
5.
Ferguson SE, Soslow RA, Amsterdam A, et al. Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol 2006; 101(2): 322–6PubMedCrossRef
6.
McMeekin DS, Alektiar KM, Sabbatini PJ, et al. Corpus: epithelial tumors. In: Barakat RR, Markman M, Randall ME, editors. Principles and practice of gynecologic oncology. Philadelphia (PA): Lipponcott, 2009: 683–732
7.
Lewin SN. Revised FIGO staging system for endometrial cancer. Clin Obstet Gynecol 2011; 54(2): 215–8PubMedCrossRef
8.
9.
American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005 Aug; 106(2): 413–25CrossRef
10.
Sorbe B, Nordström B, Mäenpää J, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer 2009; 19(5): 873–8PubMedCrossRef
11.
12.
Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 744–51PubMedCrossRef
13.
Creutzberg CL, van Putten WLJ, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomized trial. Lancet 2000; 355: 1404–11PubMedCrossRef
14.
Blake P, Swart Am, Orton J, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009; 373: 137–46PubMedCrossRef
15.
Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010; 375: 816–23PubMedCrossRef
16.
Sorbe B, Horvath G, Andersson H, et al. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma: a prospective randomised study. Int J Radiat Oncol Biol Phys 2011; 82(3): 1249–55PubMedCrossRef
17.
Ramirez PT, Frumovitz M, Bodurka DC, et al. Hormonal therapy for the management of grade 1 endometrial adeno-carcinoma: a literature review. Gynecol Oncol 2004; 95: 133–8PubMedCrossRef
18.
Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxy-progesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17: 1736–44PubMed
19.
Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2001; 19: 364–7PubMed
20.
Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 10–4PubMedCrossRef
21.
Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 4–9PubMedCrossRef
22.
Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2006; 24: 36–44PubMedCrossRef
23.
Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008; 108: 226–33PubMedCrossRef
24.
Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 2006; 95: 266–71PubMedCentralPubMedCrossRef
25.
Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 2009; 112: 543–52PubMedCrossRef
26.
Hogberg T, Signorelli M, Freire de Oliveira C, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer: results from two randomized studies. Eur J Cancer 2010; 46: 2422–31PubMedCentralPubMedCrossRef
27.
Gynecologic Oncology Group. Pelvic radiation therapy or vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with high-risk stage I or stage II endometrial cancer [ClinicalTrials.gov identifier NCT00807768]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov [Accessed 2011 Aug 7]
28.
Gynecologic Oncology Group. Carboplatin and paclitaxel with or without cisplatin and radiation therapy in treating patients with stage III or stage IVa endometrial cancer [ClinicalTrials.gov identifier NCT00942357]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov [Accessed 2011 Aug 7]
29.
Leiden University Medical Center. Chemotherapy and radiation therapy compared with radiation therapy alone in treating patients with high-risk stage I, stage II, or stage III endometrial cancer. [ClinicalTrials.gov identifier NCT00411138]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://​clinicaltrials.​gov [Accessed 2011 Sep 6]
30.
Fleming GF. Systematic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 2007; 25: 2983–90PubMedCrossRef
31.
Ball HG, Blessing JA, Lentz SS, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 62: 278–81PubMedCrossRef
32.
Lincoln S, Blessing JA, Lee RB, et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003; 88: 277–81PubMedCrossRef
33.
Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004; 22: 3902–8PubMedCrossRef
34.
Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin+cisplatin versus doxorubicin+24-h paclitaxel+filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 2004; 15: 1173–8PubMedCrossRef
35.
Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004; 22: 2159–66PubMedCrossRef
36.
Gerth K, Bedorf N, Hoe G, et al. Epothilones A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot 1996; 49: 560–3
37.
Rivera E, Lee J, Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 2008; 13: 1207–23PubMedCrossRef
38.
Lee FY, Borzilleri R, Fairchild CR, et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 2008; 63: 157–66PubMedCrossRef
39.
Lee F, Covello KL, Castaneda S, et al. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin Cancer Res 2008; 14(24): 8123–31PubMedCrossRef
40.
Hussain M, Tangen CM, Lara Jr PN, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S01 11. J Clin Oncol 2005; 23: 8724–9PubMedCrossRef
41.
Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005; 23: 1439–46PubMedCrossRef
42.
Vansteenkiste J, Lara Jr PN, Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007; 25: 3448–55PubMedCrossRef
43.
Burtness BA, Manola J, Axelrod R, et al., Eastern Cooperative Oncology Group. A randomized phase II study of ixabepilone (BMS-247550) given daily · 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol 2008; 19: 977–83PubMedCrossRef
44.
Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25: 3407–14PubMedCrossRef
45.
Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007; 25: 3399–406PubMedCrossRef
46.
Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007; 25: 3415–20PubMedCrossRef
47.
Dizon DS, Blessing JA, McMeekin DS, et al. Phase II trial of ixabepilone as second line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129-P. J Clin Oncol 2009; 27: 3104–8PubMedCentralPubMedCrossRef
48.
Bristol-Myers Squibb. A study of ixabepilone as second line therapy for locally advanced, recurrent or metastatic endometrial cancer (IXAMPLE2) [ClinicalTrials.gov identifier NCT00883116]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov [Accessed 2011 Aug 8]
49.
Gynecologic Oncology Group. Paclitaxel, carboplatin, and bevacizumab or paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab in treating patients with stage III, stage IV, or recurrent endometrial cancer [ClinicalTrials.gov identifier NCT00977574]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov [Accessed 2011 Aug 15]
50.
Hecht J, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006; 24(29): 4783–91PubMedCrossRef
51.
52.
Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009; 16(1): 8–13PubMed
53.
Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011 Aug 20; 29(24): 3278–85PubMedCentralPubMedCrossRef
54.
Colombo N, McMeekin S, Schwartz P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer [abstract no. 5516]. J Clin Oncol 2007; 25: 278
55.
Slomovitz BM, Lu KH, Johnson T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010; 116(23): 5415–9PubMedCrossRef
56.
Kamat AA, Merritt WM, Coffey D, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007; 13: 7487–95PubMedCrossRef
57.
Hirai M, Nakagawara A, Oosaki T, et al. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol 2001; 80: 181–8PubMedCrossRef
58.
Yokoyama Y, Sato S, Futagami M, et al. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol Oncol 2000; 77: 413–8PubMedCrossRef
59.
Wright JD, Powell MA, Rader JS, et al. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anti-cancer Res 2007; 27: 3525–8
60.
Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial Cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2011; 29(16): 2259–65PubMedCentralPubMedCrossRef
61.
Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008; 26: 4319–25PubMedCrossRef
62.
Leslie KK, Sill MW, Darcy KM, et al. Efficacy and safety of gefitinib (Iressa, ZD1839) and potential prognostic value of soluble EGFR, EGFR mutations and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer [abstract no. e16542]. J Clin Oncol 2009; 27 Suppl.
63.
Slomovitz B, Schmeler K, Miller D, et al. Phase II study of cetuximab (erbitux) in patients with progressive or recurrent endometrial cancer [abstract]. Gynecol Oncol 2010; 116: 13 Suppl. 1
64.
Konecny GE, Venkatesan N, Yan G, et al. Activity of lapatanib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer 2008; 98: 1076–84PubMedCentralPubMedCrossRef
65.
Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010; 116: 15–20PubMedCentralPubMedCrossRef
66.
Nimeiri H, Oza AM, Morgan RJ, et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2010; 117: 37–40PubMedCentralPubMedCrossRef
67.
Welch S, Hirte H, Schilder RJ, et al. Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: a PMH phase II consortium trial [abstract no. 5084]. J Clin Oncol 2006; 24
68.
Fleming GF, Morgan R, Wang L, et al. A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: a trial of the PMH Phase II consortium [abstract no. 5576]. J Clin Oncol 2009; 27
Metadata
Title
Medical Therapy of Endometrial Cancer
Current Status and Promising Novel Treatments
Authors
Emily K. Hill
Dr Don S. Dizon, MD
Publication date
01-03-2012
Publisher
Springer International Publishing
Published in
Drugs / Issue 5/2012
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11631840-000000000-00000

Other articles of this Issue 5/2012

Drugs 5/2012 Go to the issue

Adis Drug Evaluation

Rasagiline

Review Article

Antifungal Chemoprophylaxis in Children and Adolescents with Haematological Malignancies and Following Allogeneic Haematopoietic Stem Cell Transplantation

Systematic Review

The Cost Effectiveness of Human Papillomavirus Vaccines

Adis Drug Evaluation

Telaprevir

Adis Drug Evaluation

Tranexamic Acid

Erratum

Erratum to: Repaglinide: a review of its use in type 2 diabetes mellitus